TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation
NYSE:TAK • US8740602052
Current stock price
16.41 USD
+0.05 (+0.31%)
At close:
16.4 USD
-0.01 (-0.06%)
After Hours:
This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TAK Profitability Analysis
1.1 Basic Checks
- In the past year TAK was profitable.
- In the past year TAK had a positive cash flow from operations.
- TAK had positive earnings in each of the past 5 years.
- TAK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- TAK has a better Return On Assets (0.73%) than 81.15% of its industry peers.
- TAK has a better Return On Equity (1.48%) than 82.20% of its industry peers.
- TAK has a Return On Invested Capital of 2.32%. This is in the better half of the industry: TAK outperforms 79.58% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for TAK is significantly below the industry average of 13.10%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.73% | ||
| ROE | 1.48% | ||
| ROIC | 2.32% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
1.3 Margins
- The Profit Margin of TAK (2.53%) is better than 81.68% of its industry peers.
- TAK's Profit Margin has improved in the last couple of years.
- TAK has a Operating Margin of 10.76%. This is amongst the best in the industry. TAK outperforms 82.72% of its industry peers.
- TAK's Operating Margin has improved in the last couple of years.
- TAK's Gross Margin of 65.33% is fine compared to the rest of the industry. TAK outperforms 71.73% of its industry peers.
- In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.76% | ||
| PM (TTM) | 2.53% | ||
| GM | 65.33% |
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. TAK Health Analysis
2.1 Basic Checks
- TAK has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- TAK has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for TAK has been increased compared to 5 years ago.
- Compared to 1 year ago, TAK has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.17, we must say that TAK is in the distress zone and has some risk of bankruptcy.
- TAK has a Altman-Z score (1.17) which is in line with its industry peers.
- TAK has a debt to FCF ratio of 6.48. This is a slightly negative value and a sign of low solvency as TAK would need 6.48 years to pay back of all of its debts.
- The Debt to FCF ratio of TAK (6.48) is better than 81.68% of its industry peers.
- TAK has a Debt/Equity ratio of 0.56. This is a neutral value indicating TAK is somewhat dependend on debt financing.
- TAK's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. TAK is outperformed by 68.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 6.48 | ||
| Altman-Z | 1.17 |
ROIC/WACC1.42
WACC1.63%
2.3 Liquidity
- A Current Ratio of 1.19 indicates that TAK should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.19, TAK is not doing good in the industry: 81.68% of the companies in the same industry are doing better.
- TAK has a Quick Ratio of 1.19. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of TAK (0.65) is worse than 89.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.65 |
3. TAK Growth Analysis
3.1 Past
- TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.17%.
- The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
- Looking at the last year, TAK shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.
- TAK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.84% yearly.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
3.2 Future
- The Earnings Per Share is expected to grow by 44.51% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 0.47% on average over the next years.
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. TAK Valuation Analysis
4.1 Price/Earnings Ratio
- TAK is valuated quite expensively with a Price/Earnings ratio of 71.35.
- Based on the Price/Earnings ratio, TAK is valued a bit cheaper than 78.01% of the companies in the same industry.
- TAK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.91.
- TAK is valuated quite expensively with a Price/Forward Earnings ratio of 29.09.
- Based on the Price/Forward Earnings ratio, TAK is valued a bit cheaper than the industry average as 74.87% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of TAK to the average of the S&P500 Index (21.99), we can say TAK is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 71.35 | ||
| Fwd PE | 29.09 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 88.48% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, TAK is valued cheaper than 89.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.02 | ||
| EV/EBITDA | 9.95 |
4.3 Compensation for Growth
- TAK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- TAK has an outstanding profitability rating, which may justify a higher PE ratio.
- TAK's earnings are expected to grow with 44.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.93
PEG (5Y)3.72
EPS Next 2Y62.14%
EPS Next 3Y44.51%
5. TAK Dividend Analysis
5.1 Amount
- TAK has a Yearly Dividend Yield of 3.75%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 0.73, TAK pays a better dividend. On top of this TAK pays more dividend than 95.81% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, TAK pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.75% |
5.2 History
- The dividend of TAK has a limited annual growth rate of 1.18%.
- TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
- TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
- TAK pays out 277.04% of its income as dividend. This is not a sustainable payout ratio.
- TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP277.04%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
TAK Fundamentals: All Metrics, Ratios and Statistics
16.41
+0.05 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30 2026-01-30/dmh
Earnings (Next)05-13 2026-05-13/bmo
Inst Owners48.8%
Inst Owner Change-0.04%
Ins Owners0%
Ins Owner Change0%
Market Cap51.84B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target20.07 (22.3%)
Short Float %0.15%
Short Ratio1.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.75% |
Yearly Dividend0.6
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years3
Div Non Decr Years4
Ex-Date03-30 2026-03-30 (100)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)10.43%
PT rev (3m)21.52%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-17.21%
EPS NY rev (1m)1.43%
EPS NY rev (3m)1.69%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 71.35 | ||
| Fwd PE | 29.09 | ||
| P/S | 1.85 | ||
| P/FCF | 11.02 | ||
| P/OCF | 6.94 | ||
| P/B | 1.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.95 |
EPS(TTM)0.23
EY1.4%
EPS(NY)0.56
Fwd EY3.44%
FCF(TTM)1.49
FCFY9.07%
OCF(TTM)2.36
OCFY14.41%
SpS8.88
BVpS15.2
TBVpS-3.23
PEG (NY)0.93
PEG (5Y)3.72
Graham Number8.86763 (-45.96%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.73% | ||
| ROE | 1.48% | ||
| ROCE | 3.75% | ||
| ROIC | 2.32% | ||
| ROICexc | 2.47% | ||
| ROICexgc | 10.72% | ||
| OM | 10.76% | ||
| PM (TTM) | 2.53% | ||
| GM | 65.33% | ||
| FCFM | 16.77% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 6.48 | ||
| Debt/EBITDA | 3.48 | ||
| Cap/Depr | 58.95% | ||
| Cap/Sales | 9.86% | ||
| Interest Coverage | 4.11 | ||
| Cash Conversion | 96.87% | ||
| Profit Quality | 663% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z | 1.17 |
F-Score5
WACC1.63%
ROIC/WACC1.42
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year442.96%
EBIT Next 3Y77.92%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK Fundamental Analysis FAQ
What is the fundamental rating for TAK stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status for TAK stock?
ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
How profitable is TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.
What is the earnings growth outlook for TAKEDA PHARMACEUTIC-SP ADR?
The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 77.07% in the next year.
Is the dividend of TAKEDA PHARMACEUTIC-SP ADR sustainable?
The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 6 / 10 and the dividend payout ratio is 277.04%.